Morphic Medical, Inc.
GIDYL
OTC PK
| 03/31/2021 | 12/31/2020 | 09/30/2020 | 06/30/2020 | 03/31/2020 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 5.23M | 5.62M | 6.28M | 5.73M | 5.50M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 8.46M | 9.11M | 10.16M | 10.37M | 10.09M |
| Operating Income | -8.46M | -9.11M | -10.16M | -10.37M | -10.09M |
| Income Before Tax | -10.65M | -11.11M | -11.76M | -10.89M | -17.80M |
| Income Tax Expenses | 19.00K | 24.00K | 28.00K | 23.00K | 44.00K |
| Earnings from Continuing Operations | -10.66 | -11.14 | -11.79 | -10.92 | -17.84 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -10.66M | -11.14M | -11.79M | -10.92M | -17.84M |
| EBIT | -8.46M | -9.11M | -10.16M | -10.37M | -10.09M |
| EBITDA | -8.40M | -9.04M | -10.10M | -10.30M | -10.02M |
| EPS Basic | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Normalized Basic EPS | 0.00 | 0.00 | -0.01 | -0.01 | -0.01 |
| EPS Diluted | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Normalized Diluted EPS | 0.00 | 0.00 | -0.01 | -0.01 | -0.01 |
| Average Basic Shares Outstanding | 14.33B | 11.76B | 7.82B | 5.71B | 4.85B |
| Average Diluted Shares Outstanding | 716.66B | 587.92B | 391.11B | 285.66B | 242.36B |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
